greeksoup/ stocks
Stocks / India / TORNTPHARM / Q2 FY2024

Torrent Pharmaceuticals Ltd. Q2 FY2024 results: revenue ₹2,660 crore, up 16.1% on the year

Torrent Pharmaceuticals Ltd. (TORNTPHARM) reported consolidated revenue from operations of ₹2,660 crore for Q2 FY2024, the quarter ended 30 September 2023, up 16.1% on the same quarter a year earlier. Profit after tax was ₹386 crore, up 23.7% on the year, and earnings per share ₹11.39. The figures are the company's own, from the unaudited results it filed with NSE on 25 October 2023.

Revenue from operations₹2,660 croreup 16.1%
Profit after tax₹386 croreup 23.7%
EPS₹11.39
QuarterQ2 FY2024ended 30 September 2023

The quarter, against the one before and a year earlier

LineQ2 FY2024Quarter beforeA year earlierChange on the year
Revenue from operations2,660n/an/an/a
Other income26n/an/an/a
Total income2,686n/an/an/a
Cost of materials consumed433n/an/an/a
Purchases of stock-in-trade292n/an/an/a
Changes in inventories-65n/an/an/a
Employee benefit expense503n/an/an/a
Finance costs91n/an/an/a
Depreciation, depletion and amortisation201n/an/an/a
Other expenses672n/an/an/a
Total expenses2,127n/an/an/a
Profit before exceptional items and tax559n/an/an/a
Exceptional items0n/an/an/a
Profit before tax559n/an/an/a
Current tax120n/an/an/a
Deferred tax53n/an/an/a
Total tax173n/an/an/a
Profit after tax386n/an/an/a
Attributable to owners of the parent363n/an/an/a
Other comprehensive income-23n/an/an/a
Total comprehensive income363n/an/an/a
EPS, basic₹11.39n/an/an/a
EPS, diluted₹11.39n/an/an/a

₹ crore except per share.

Leverage, as the company states it

LineQ2 FY2024Quarter beforeA year earlierChange on the year
Debt to equity0.01n/an/a
Debt service coverage0.04n/an/a
Interest service coverage0.08n/an/a

Debt to equity, debt service coverage and interest service coverage are the figures the company prints in its result statement under the listing regulations.

Quarterly results, the last 12 quarters

Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Sales2,6602,7322,7452,8592,8892,8092,9593,1783,3023,3034,1974,921
Expenses2,1272,1562,1452,2272,2122,1512,2522,4032,4712,4663,5854,155
Operating profit8258698839049399149641,0321,0831,0881,3561,664
OPM %31%32%32%32%33%33%33%32%33%33%32%34%
Other income26-333124-1633-18-37-27-13-17-12
Interest91808075645756564845236305
Depreciation201213203197198199201201204206508593
Exceptional items0880000-240-13-10-66-21
Profit before tax559631631656661691665738791814529733
Tax %31%30%29%30%31%27%25%26%25%22%31%23%
Net profit386443449457453503498548591635364566
EPS in ₹₹11.39₹13.10₹13.27₹13.51₹13.37₹14.88₹14.71₹16.19₹17.45₹18.77₹11.51₹14.87
FilingNSENSENSENSENSENSEFilingFilingFilingFilingFilingFiling

₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.

Source

Unaudited consolidated results for the quarter ended 30 September 2023, filed with NSE on 25 October 2023: the result statement. All of Torrent Pharmaceuticals Ltd.'s results: NSE company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install